Supernus Pharmaceuticals Announces Issuance Of Third US Patent Protecting Trokendi XR
Published: Mar 12, 2014
ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a third patent (number 8,663,683) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR™, its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on March 04, 2014. It provides protection for the product with expiration that is no earlier than 2027.
Help employers find you! Check out all the jobs and post your resume.